Immunicum recruits a new Chief Operating Officer

        Print
| Source: Immunicum AB
multilang-release

Gothenburg, 2013-07-01 09:51 CEST (GLOBE NEWSWIRE) -- Immunicum AB (publ), which develops therapeutic cancer vaccines, has appointed Henrik Elofsson as new Chief Operating Officer (COO).

As COO, Henrik Elofsson will be responsible for project management regarding preclinical and clinical trials. He will also be responsible for the establishment of a large-scale production process.

Henrik Elofsson has an educational background in Biomedicine from Linköping University and a M.Sc. from Chalmers School of Entrepreneurship, Bioscience Venture Creation Track. He comes from Arterion where he worked as vice president in charge of R&D and the establishment of new production processes. He was also a Board member. Henrik has worked as a consultant to several innovation projects and has acted as a coach to many business developers in Life Science.

- We are very pleased to have recruited Henrik as Chief Operating Officer in this very exciting and intense stage that Immunicum is in. We are nearing completion of an ongoing clinical trial in kidney cancer patients and also hope to start another clinical trial in liver cancer patients shortly. Henrik will, among other things, focus on increasing patient recruitment in our clinical studies. In addition, we are planning a phase II study in kidney cancer patients so Henrik is important in strengthening of our team as we are stepping up efforts to exploit the vast potential of our technology platforms, says Jamal El-Mosleh, CEO of Immunicum.

In connection with his employment, Henrik Elofsson, acquired shares in the Company.

Immunicums patented vaccine is based on over 30 years of research in the field of transplantation immunology and activates the body's own immune system to attack harmful substances like tumor cells. In February 2012, Immunicum initiated its first clinical phase I/II-study with INTUVAX® in metastatic renal cancer where today 10 out of 12 patients have been treated, so far with promising results. During the summer, a decision from the Swedish Medical Products Agency is expected concerning an application to start another phase I/II-study in primary liver cancer.

Immunicum’s patented vaccine is based on over 30 years of research in the field of transplantation immunology and activates the body's own immune system to attack harmful substances like tumor cells. Immunicum’s shares have been traded since April 22, 2013 at NASDAQ OMX First North under the ticker IMMU.

G&W Fondkommission is chosen as the Company’s Certified Adviser.

Tel: +468-503 000 50. www.gwkapital.se.

For further information please contact:

Jamal El-Mosleh, CEO of Immunicum, 0703-31 90 51,
jamal.el-mosleh@immunicum.com

About Immunicum AB (publ):

Immunicum AB (publ) develops cancer immunotherapies. Its two main groups of therapeutic cancer vaccines, SUBCUVAX® and INTUVAX®, and the method of expansion of tumor-specific T-cells (CD70) is based on the Nobel prize awarded discovery of the dendritic cell and its central role in the activation of the specific immune response. Because the raw material consists of dendritic cells from healthy donors, Immunicum’s products can be produced in large scale. The vaccines have earlier proven efficacy in animal studies and are now undergoing clinical trials in patients.

www.immunicum.com